Johnson & Johnson (NYSE:JNJ) has announced that its late-stage trial for Tecvayli (teclistamab), used in combination with Darzalex Faspro, achieved its main goal in treating relapsed or refractory multiple myeloma.
This combination was compared to the investigator’s choice of either Darzalex Faspro with pomalidomide and dexamethasone or Darzalex Faspro with bortezomib and dexamethasone.
Additionally, the secondary endpoint concerning overall survival showed statistically significant results during the first interim analysis.
The company said that the safety profile of the treatment combination was consistent with the known safety profiles of each monotherapy.
